Replimune Stock Soars 85.7% After FDA Agrees BLA Resubmission for RP1
REPL•Replimune Group shares jumped 85.7% after the FDA agreed to a BLA resubmission for its RP1 oncolytic immunotherapy for advanced melanoma. Analysts expect Q2 EPS of -$0.73 and $5.57 million in revenue, reflecting continued R&D focus ahead of the next regulatory review.
1. FDA Agrees to BLA Resubmission
The U.S. Food and Drug Administration has agreed to allow Replimune to resubmit its Biologics License Application for RP1, marking a crucial regulatory step toward potential market approval of its oncolytic immunotherapy for advanced melanoma.
2. Stock Market Reaction
Shares of Replimune surged 85.7% in trading following the announcement, reflecting strong investor confidence in the drug candidate’s prospects and the significance of the FDA’s decision.
3. Financial Outlook
Analysts forecast a Q2 earnings per share loss of $0.73 and revenues of $5.57 million, underscoring the company’s current development-stage status and heavy investment in research and development.
4. Clinical Data Basis
The BLA resubmission is supported by positive results from the pivotal IGNYTE clinical trial, which evaluated RP1 in combination with existing melanoma therapies and demonstrated encouraging efficacy signals.
